Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rain’s objective is to identify cancers with clear and identifiable genetic vulnerabilities and evaluate sub-populations of cancer populations with an unmet need, where standards of care are ineffective.
Rain’s lead program is RAIN-32, a small molecule MDM2 inhibitor initially being developed for patients with well-differentiated and de-differentiated liposarcoma, as well as other indications exhibiting MDM2 gene amplification or overexpression. RAIN-32 has been evaluated in clinical trials in certain solid tumors and hematological malignancies and previously demonstrated a novel dosing regimen for improved tolerability.
Rain is also developing tarloxotinib, a hypoxia-activated pan-HER inhibitor in clinical trials for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 activating mutations, as well as a tumor-agnostic cohort for patients with NRG1, EGFR, HER2, and HER4 fusions.
Preclinically, Rain is researching potential first-in-class inhibitors of RAD52 in the DNA Damage Response (DDR) pathway as a synthetic lethal strategy for tumors with BRCA1/2 mutations and other Homologous Repair Deficiencies (HRD).